Bifeprunox is a novel atypical antipsychotic agent which, along with SLV313, aripiprazole and SSR-181507 combines minimal D2 receptor agonism with 5-HT receptor agonism.
Bifeprunox is being evaluated for the treatment of schizophrenia, psychosis, and Parkinson's disease.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.